Microsoft, Novartis partner for AI-powered drug discovery, development

Listen
Text
  • Small
  • Medium
  • Large

Novartis will establish an artificial intelligence innovation lab, in partnership with Microsoft, in which researchers will combine Microsoft's AI technology and Novartis' life sciences expertise to accelerate the development of new medicines.

The partnership's objective is twofold: to empower Novartis' drug discovery and development team with the help of advanced AI software, and to use AI to explore and speed the development of potential new gene and cell therapies. Microsoft's AI will be applied to every stage of the development process, including research, clinical trials and manufacturing.

"As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients' lives," Novartis CEO Vas Narasimhan, MD, said. "Pairing our deep knowledge of human biology and medicine with Microsoft's leading expertise in AI could transform the way we discover and develop medicines for the world."

More articles on AI:
Penn Medicine predictive system increases palliative care consults by 74%
AHA: 6 crucial components for integrating AI into healthcare workforce
Mayo Clinic joins $20M funding for startup fighting heart disease with AI

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars